What's new? Log in Free sign up

Profound Medical (PROF)

Company Profile

Company profile

Ticker

PROF, PRN

Exchange

Website

www.profoundmedical.com

CEO

Dr. Arun Swarup Menawat MBA, Ph.D.

Incorporated

Ontario, Canada

Location

Ontario, Canada

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...

Former names

LegalApp Holdings, Inc.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PROF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Material Change Report

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Current report (foreign)

Supplemental materials (foreign)

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Current report (foreign)

Supplemental materials (foreign)

Profound Medical Announces Proposed Public Offering of Common Shares

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

GAGNON SECURITIES LLC

GAGNON SECURITIES LLC

Notice of proposed sale of securities

LETKO, BROSSEAU & ASSOCIATES INC

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

BDC CAPITAL INC.

Notice of proposed sale of securities

Financial summary

Financial statements Chart PROF financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PROF institutional ownership history Ownership history

36.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	46	41	+12.2%
Opened positions	10	5	+100.0%
Closed positions	5	8	-37.5%
Increased positions	12	12	–
Reduced positions	8	8	–

13F shares	Current	Prev Q	Change
Total value	74.98 bn	80.13 bn	-6.4%
Total shares	11.10 mm	9.97 mm	+11.3%
Total puts	5.00 k	0.00	NEW
Total calls	1.20 k	22.90 k	-94.8%
Total put/call ratio	4.2	–	–

Largest owners	Shares	Value	Change
FIL	1.54 mm	$12.21 bn	+2.0%
Gagnon Securities	1.47 mm	$11.68 bn	-2.7%
BDC Capital	1.22 mm	$13.09 mm	NEW
Letko, Brosseau & Associates	1.20 mm	$9.55 bn	0.0%
Raymond James Financial Services Advisors	760.46 k	$6.05 bn	+11.6%
Timelo Investment Management	751.81 k	$5.98 bn	+3.6%
Gagnon Advisors	747.23 k	$5.95 bn	0.0%
Royce & Associates	569.30 k	$4.53 bn	+0.6%
Rosalind Advisors	485.97 k	$3.87 bn	-8.9%
Genesys Ventures II	455.74 k	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
BDC Capital	1.22 mm	+1.22 mm	NEW
AIGH Capital Management	0.00	-646.73 k	EXIT
TD Asset Management	124.30 k	+124.30 k	NEW
Raymond James Financial Services Advisors	760.46 k	+78.90 k	+11.6%
Connor, Clark & Lunn Investment Management	76.90 k	+76.90 k	NEW
Ardsley Advisory Partners	275.00 k	+60.00 k	+27.9%
Renaissance Technologies	58.90 k	+58.90 k	NEW
Millennium Management	53.63 k	+53.63 k	NEW
K2 Principal Fund	50.00 k	+50.00 k	NEW
Rosalind Advisors	485.97 k	-47.36 k	-8.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Profound Medical Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGARTORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF)

Press releases

From Benzinga Pro

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.